Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Olmesartan
Accession Number
DB00275  (APRD00223)
Type
Small Molecule
Groups
Approved, Investigational
Description

Olmesartan is a nonpeptide antihypertensive with no chiral centers.[2] Orally available olmesartan is usually presented in the form of olmesartan medoxomil which is a prodrug rapidly converted in vivo to the pharmacologically active olmesartan.[1] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[3, 4]

Structure
Thumb
Synonyms
  • 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
  • 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
  • Olmesartan
External IDs
DE-092 / RNH-6270
Product Ingredients
IngredientUNIICASInChI Key
Olmesartan medoxomil6M97XTV3HD144689-63-4UQGKUQLKSCSZGY-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act OlmesartanTablet20 mgOralTeva2017-05-01Not applicableCanada
Act OlmesartanTablet40 mgOralTeva2017-05-01Not applicableCanada
BenicarTablet, film coated40 mg/1Oralbryant ranch prepack2002-04-25Not applicableUs63629 335720180913 8702 a1asne
BenicarTablet, film coated5 mg/1OralMed Pharma Co., Ltd.2012-02-02Not applicableUs
BenicarTablet, film coated20 mg/1OralMed Pharma Co., Ltd.2012-02-02Not applicableUs
BenicarTablet, film coated40 mg/1OralMed Pharma Co., Ltd.2012-02-02Not applicableUs65597 0104 90 nlmimage10 14130a78
BenicarTablet, film coated40 mg/1OralPD-Rx Pharmaceuticals, Inc.2002-04-25Not applicableUs
BenicarTablet, film coated20 mg/1OralRemedy Repack2013-10-042014-10-04Us65597 0103 90 nlmimage10 12130928
BenicarTablet, film coated20 mg/1OralA-S Medication Solutions2002-04-25Not applicableUs54569 560620180907 15195 1hjkrfq
BenicarTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2004-01-30Not applicableUs54868 498620180906 25352 avunk1
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-olmesartanTablet20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-olmesartanTablet40 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Apo-olmesartanTablet10 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-olmesartanTablet20 mgOralApotex Corporation2017-05-31Not applicableCanada
Apo-olmesartanTablet40 mgOralApotex Corporation2017-05-30Not applicableCanada
Auro-olmesartanTablet5 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-olmesartanTablet20 mgOralAuro Pharma Inc2017-05-01Not applicableCanada
Auro-olmesartanTablet40 mgOralAuro Pharma Inc2017-05-01Not applicableCanada
Jamp-olmesartanTablet20 mgOralJamp Pharma Corporation2017-05-10Not applicableCanada
Jamp-olmesartanTablet40 mgOralJamp Pharma Corporation2017-05-10Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ach-olmesartan HctzOlmesartan medoxomil (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-olmesartan HctzOlmesartan medoxomil (40 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAccord Healthcare LimitedNot applicableNot applicableCanada
Ach-olmesartan HctzOlmesartan medoxomil (40 mg) + Hydrochlorothiazide (25 mg)TabletOralAccord Healthcare LimitedNot applicableNot applicableCanada
Act Olmesartan HCTOlmesartan medoxomil (20 mg) + Hydrochlorothiazide (12.5 mg)TabletOralTeva2017-05-01Not applicableCanada
Act Olmesartan HCTOlmesartan medoxomil (40 mg) + Hydrochlorothiazide (12.5 mg)TabletOralTeva2017-05-01Not applicableCanada
Act Olmesartan HCTOlmesartan medoxomil (40 mg) + Hydrochlorothiazide (25 mg)TabletOralTeva2017-05-01Not applicableCanada
Amlodipine and Olmesartan MedoxomilOlmesartan medoxomil (20 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralSun Pharmaceutical Industries, Inc.2016-10-26Not applicableUs
Amlodipine and Olmesartan MedoxomilOlmesartan medoxomil (20 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralSun Pharmaceutical Industries, Inc.2016-10-26Not applicableUs
Amlodipine and Olmesartan MedoxomilOlmesartan medoxomil (40 mg/1) + Amlodipine besylate (5 mg/1)Tablet, film coatedOralSun Pharmaceutical Industries, Inc.2016-10-26Not applicableUs
Amlodipine and Olmesartan MedoxomilOlmesartan medoxomil (40 mg/1) + Amlodipine besylate (10 mg/1)Tablet, film coatedOralSun Pharmaceutical Industries, Inc.2016-10-26Not applicableUs
International/Other Brands
Erastapex (Apex Pharma) / Golme (Golgi USA Research Laboratories Ltd) / Olmy (Zydus Cadila) / Olsar (Unichem Laboratories) / Olvance (Ranbaxy Laboratories Ltd) / WinBP (Abbott Healthcare Pvt Ltd)
Categories
UNII
8W1IQP3U10
CAS number
144689-24-7
Weight
Average: 446.5016
Monoisotopic: 446.206638728
Chemical Formula
C24H26N6O3
InChI Key
VTRAEEWXHOVJFV-UHFFFAOYSA-N
InChI
InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
IUPAC Name
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid
SMILES
CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O

Pharmacology

Indication

Olmesartan is indicated for the treatment of hypertension either alone or associated with other antihypertensive agents.[Label]

Hypertension is a sustained elevation of resting blood pressure. The hypertensive effect can affect the systolic blood pressure, diastolic blood pressure or both. This condition tends to be asymptomatic until it reaches a severe or long-standing state.[7]

Associated Conditions
Pharmacodynamics

The activities of olmesartan directly antagonize the angiotensin-mediated contraction in a dose-dependent manner. The activity of olmesartan can produce inhibition of 90% of the muscle contractility for at least 90 minutes.[2]

Preclinical studies driven by inhibition of nitric oxide synthesis showed that olmesartan inhibits the angiotensin II-induced pressor response which in order prevents the production of markers of early cardiovascular inflammation, myocardial remodeling, and cardiac fibrosis. It also reduced the protein urinary secretion, the area of aortic plaque lesions and the intimal thickening in cross-sections of the aorta.[2]

In clinical trials made on hypertensive patients following a low-sodium diet, olmesartan was observed to significantly decrease diastolic blood pressure when compared with placebo-treated patients.[1] As well, the administration of olmesartan was shown to lower the mean 24 hours ambulatory blood pressure and to increase renin and angiotensin II concentrations in plasma.[2]

Mechanism of action

Olmesartan is a selective angiotensin II-type I receptor blocker with a large affinity. It has been shown to present an IC50 of 8 nmol/L while showing a very minimal affinity towards angiotensin-II type II receptor. The blockage of olmesartan is done by the displacement of angiotensin II converting it hence, in a competitive antagonist.[1]

The activity of olmesartan is mainly performed in vascular smooth muscle cells and hence its activity prevents the vasoconstrictor effects of angiotensin II.[2]

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Humans
Absorption

Olmesartan, in the form of olmesartan medoxomil is rapidly absorbed in the gastrointestinal tract and metabolized to olmesartan. The esterification with medoxomil was created with the intention of increasing olmesartan bioavailability from 4.5% to 28.6%.[1]

Oral administration of 10-160 mg of olmesartan has been shown to reach peak plasma concentration of 0.22-2.1 mg/L after 1-3 hours with an AUC of 1.6-19.9mgh/L.[2] The pharmacokinetic profile of olmesartan has been observed to be nearly linear and dose-dependent under the therapeutic range.[1] The steady-state level of olmesartan is achieved after once a day dosing during 3 to 5 days.[6]

Volume of distribution

The reported volume of distribution of olmesartan is of 17 L.[6]

Protein binding

Olmesartan is highly bound to plasma proteins hence, even 99% of the administered dose is found in a bound state with no penetration in red blood cells.[6]

Metabolism

Olmesartan is rapidly and completely bioactivated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. This rapid first-pass metabolism was confirmed by the lack of measurable amounts of olmesartan medoxomil in plasma or excreta.[1] This first-pass metabolism is not driven by cytochrome enzymes and hence it is not expected to interact with other drugs via this mechanism.[2]

The pharmacologically active moiety has shown to not present further metabolism.[1]

Route of elimination

The main elimination route of olmesartan is in the unchanged form through the feces. From the systemically bioavailable dose, about 10-16% is eliminated in the urine.[1]

Half life

The mean plasma olmesartan half-life is reported to be from 10-15 hours after multiple oral administration.[1]

Clearance

Total plasma clearance of olmesartan is reported to be of 1.3 L/h and the renal clearance is 0.6 L/h.[6]

Toxicity

The reported LD50 of olmesartan in dogs was reported to be greater of 1500 mg/kg. Overdose is expressed as hypotension, tachycardia, and bradycardia when there is parasympathetic stimulation. In case of overdose, supportive treatment is recommended.[Label]

Olmesartan was shown to be safe on carcinogenic and fertility studies. However, in in vitro mutagenic studies showed a potential to induce chromosomal aberrations in cells and it tested positive for thymidine kinase mutations in the mouse lymphoma assay.[Label]

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Olmesartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of adverse effects can be increased when Olmesartan is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazole1-benzylimidazole may decrease the antihypertensive activities of Olmesartan.
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the antihypertensive activities of Olmesartan.
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the antihypertensive activities of Olmesartan.
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the antihypertensive activities of Olmesartan.
4-Methoxyamphetamine4-Methoxyamphetamine may decrease the antihypertensive activities of Olmesartan.
5-methoxy-N,N-dimethyltryptamine5-methoxy-N,N-dimethyltryptamine may decrease the antihypertensive activities of Olmesartan.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Olmesartan.
AbediterolAbediterol may decrease the antihypertensive activities of Olmesartan.
AcebutololThe risk or severity of hyperkalemia can be increased when Olmesartan is combined with Acebutolol.
Food Interactions
  • Food does not affect the bioavailability of olmesartan.

References

Synthesis Reference
US20060069141
General References
  1. Brunner HR: The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens. 2002 May;16 Suppl 2:S13-6. doi: 10.1038/sj.jhh.1001391. [PubMed:11967728]
  2. Brunner HR: Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag. 2006;2(4):327-40. [PubMed:17323586]
  3. Gonakoti S, Khullar S, Rajkumar A: Olmesartan Associated Enteropathy: A Rare Underdiagnosed Cause of Diarrhea and Weight Loss. Am J Case Rep. 2019 Jan 26;20:111-116. doi: 10.12659/AJCR.913207. [PubMed:30683835]
  4. FDA approvals [Link]
  5. FDA chemical report [Link]
  6. FDA pharmacology report [Link]
  7. Merck Manuals [Link]
External Links
Human Metabolome Database
HMDB0014420
KEGG Drug
D01204
PubChem Compound
158781
PubChem Substance
46508275
ChemSpider
139674
BindingDB
50241364
ChEBI
48416
ChEMBL
CHEMBL1516
Therapeutic Targets Database
DAP001412
PharmGKB
PA164742950
HET
OLM
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Olmesartan
ATC Codes
C09DA08 — Olmesartan medoxomil and diureticsC09DX03 — Olmesartan medoxomil, amlodipine and hydrochlorothiazideC09CA08 — Olmesartan medoxomilC09DB02 — Olmesartan medoxomil and amlodipine
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
PDB Entries
4zud
FDA label
Download (286 KB)
MSDS
Download (509 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers7
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHigh Blood Pressure (Hypertension)1
1Not Yet RecruitingBasic ScienceHealthy Volunteers1
2CompletedTreatmentChronic Glomerulonephritis / Diabetic Nephropathies1
2CompletedTreatmentHigh Blood Pressure (Hypertension)4
2Not Yet RecruitingTreatmentCoronary Syndrome1
2RecruitingTreatmentStroke, Ischemic1
2, 3CompletedTreatmentHigh Blood Pressure (Hypertension)1
3CompletedPreventionCardiovascular Disease (CVD) / Kidney Diseases / Type 2 Diabetes Mellitus1
3CompletedTreatmentArrythmias / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentAtherosclerosis1
3CompletedTreatmentAtherosclerotic Cardiovascular Diseases / Hypertension,Essential1
3CompletedTreatmentChronic Heart Failure (CHF)1
3CompletedTreatmentDiabetic Nephropathies / Kidney Diseases / Proteinuria / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetic Nephropathies / Proteinuria / Type 2 Diabetes Mellitus1
3CompletedTreatmentDyslipidemias / High Blood Pressure (Hypertension)1
3CompletedTreatmentHigh Blood Pressure (Hypertension)7
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes2
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Safety and Efficacy og Azilsartan in Chinese Hypertension Patients1
3CompletedTreatmentHypertension,Essential14
3CompletedTreatmentHypertension,Essential / Impaired Renal Function1
3CompletedTreatmentSafety1
3Not Yet RecruitingTreatmentArterial Hypertension1
3Not Yet RecruitingTreatmentEssential Arterial Hypertension1
3RecruitingTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias1
3Unknown StatusTreatmentHypertension,Essential1
4CompletedNot AvailableHigh Blood Pressure (Hypertension)1
4CompletedPreventionBMI >27 kg/m2 / High Blood Pressure (Hypertension) / Obese / Prehypertension1
4CompletedPreventionCardiovascular Disease (CVD) / High Blood Pressure (Hypertension)1
4CompletedTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD) / Hypertension,Essential / Strokes1
4CompletedTreatmentDrug Interaction of Olmesartan in Healthy Chinese Volunteers1
4CompletedTreatmentEssential,Hypertension1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHigh Blood Pressure (Hypertension)9
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4RecruitingPreventionBlood Pressures / High Blood Pressure (Hypertension) / Strokes1
4RecruitingTreatmentEfficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension1
4RecruitingTreatmentOsteoporosis / Postmenopausal Osteoporosis (PMO)1
4TerminatedTreatmentCarotid Plaques / Hypertension,Essential1
4TerminatedTreatmentPeripheral Artery Disease With Intermittent Claudication1
4Unknown StatusTreatmentCoronary Artery Atherosclerosis1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)2
4WithdrawnTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableExercise Training / Vascular Function1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHypertension,Essential1
Not AvailableCompletedPreventionImpaired Glucose Tolerance (IGT) / Prediabetic State1
Not AvailableCompletedTreatmentAmbulatory Blood Pressure Monitoring / Arterial Stiffness1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Obstructive Sleep Apnea (OSA)1
Not AvailableCompletedTreatmentHypertension,Essential1
Not AvailableUnknown StatusNot AvailableHigh Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
  • Daiichi sankyo inc
  • Daiichi Sankyo
Packagers
  • Bryant Ranch Prepack
  • Cardinal Health
  • Daiichi Sankyo
  • DispenseXpress Inc.
  • Dispensing Solutions
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Physicians Total Care Inc.
  • Quality Care
  • Resource Optimization and Innovation LLC
  • Schering-Plough Inc.
  • Southwood Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral10 mg
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, coatedOral20 mg/1
Tablet, coatedOral40 mg/1
Tablet, coatedOral5 mg/1
TabletOral20 mg
TabletOral40 mg
TabletOral5 mg
TabletOral
Prices
Unit descriptionCostUnit
Benicar 5 mg tablet12.81USD tablet
Benicar hct 40-25 mg tablet4.93USD tablet
Benicar hct 40-12.5 mg tablet4.67USD tablet
Benicar hct 20-12.5 mg tablet3.94USD tablet
Benicar 40 mg tablet3.74USD tablet
Benicar 20 mg tablet2.97USD tablet
Olmetec 20 mg Tablet1.04USD tablet
Olmetec 40 mg Tablet1.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2061607No1999-01-192012-02-20Canada
US5616599Yes1997-04-012016-10-25Us
US6878703Yes2005-04-122022-05-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)177.6 ºC'MSDS'
boiling point (°C)800 ºC at 760 mm Hg'MSDS'
water solubilityInsolubleFDA Chemical report
logP0.73FDA Pharmacological report
pKa4.3FDA Chemical report
Predicted Properties
PropertyValueSource
Water Solubility0.0105 mg/mLALOGPS
logP2.98ALOGPS
logP2.14ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)0.91ChemAxon
pKa (Strongest Basic)5.57ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area129.81 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity137.32 m3·mol-1ChemAxon
Polarizability47.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.8719
Caco-2 permeable-0.6865
P-glycoprotein substrateSubstrate0.7247
P-glycoprotein inhibitor INon-inhibitor0.5917
P-glycoprotein inhibitor IIInhibitor0.6029
Renal organic cation transporterNon-inhibitor0.807
CYP450 2C9 substrateNon-substrate0.7429
CYP450 2D6 substrateNon-substrate0.8602
CYP450 3A4 substrateNon-substrate0.5149
CYP450 1A2 substrateNon-inhibitor0.782
CYP450 2C9 inhibitorInhibitor0.5816
CYP450 2D6 inhibitorNon-inhibitor0.8059
CYP450 2C19 inhibitorInhibitor0.6604
CYP450 3A4 inhibitorInhibitor0.7409
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8396
Ames testNon AMES toxic0.6203
CarcinogenicityNon-carcinogens0.6871
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6599 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9254
hERG inhibition (predictor II)Non-inhibitor0.6427
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a6r-0692700000-11f020dfbb889ac85e4e

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenyltetrazoles and derivatives / 1,2,4,5-tetrasubstituted imidazoles / Carbonylimidazoles / N-substituted imidazoles / Tertiary alcohols / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Biphenyl / Phenyltetrazole / 1,2,4,5-tetrasubstituted imidazole / Imidazole-4-carbonyl group / N-substituted imidazole / Azole / Imidazole / Heteroaromatic compound / Tertiary alcohol / Tetrazole
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
biphenylyltetrazole (CHEBI:48416)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Koike H, Sada T, Mizuno M: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens Suppl. 2001 Jun;19(1):S3-14. [PubMed:11451212]
  3. Ochiai K, Hu Q, Lee J, Mansoor A, Liu J, Wang X, Gong G, Murakami Y, Ishibashi Y, Shimada T, Zhang J: Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling. J Cardiovasc Pharmacol. 2006 May;47(5):686-94. [PubMed:16775509]
  4. Warner GT, Jarvis B: Olmesartan medoxomil. Drugs. 2002;62(9):1345-53; discussion 1354-6. [PubMed:12076183]
  5. Mire DE, Silfani TN, Pugsley MK: A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005 Nov;46(5):585-93. [PubMed:16220064]
  6. Kreutz R, Bolbrinker J, Huber M: Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clin Drug Investig. 2006;26(1):29-34. [PubMed:17163232]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. FDA pharmacology report [Link]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053]
  2. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24. [PubMed:16501004]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on April 23, 2019 16:39